Bladder Carcinoma — Trials

Bladder Carcinoma — Trials · CancerIndex

Clinical trials

Registered studies

332 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.

Active: 141
Recruiting: 74
Ph III recruiting: 14
Growth YoY: +6.5%
Industry share: 18%
Top sponsor: National Cancer Institute (NCI)
Termination share: 48.5%

Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancers Terminated studies (49)

clinicaltrialsPublishedShowing 1–4 of 4 studies matching the filters · status and phase as posted by the registrant; each row links to the study record.

NCT	Title	Status	Phase	Enrollment (n)	Sponsor	Countries	Last update	Source
NCT05311618	Study of NGM438 as Monotherapy and in Combination With Pembrolizumab in Advanced or Metastatic Solid Tumors	unknown	Phase 1	71	NGM Biopharmaceuticals, IncINDUSTRY	1	Apr 1, 2024	clinicaltrials
NCT03549715	NEoadjuvant Dose-dense MVAC In cOmbination With Durvalumab and Tremelimumab in Muscle-invasive Urothelial Carcinoma(NEMIO)	unknown	Phase 1 / Phase 2	121	Association Pour La Recherche des Thérapeutiques Innovantes en CancérologieOTHER